PAVmed Inc. (PAVM)
| Market Cap | 405.71M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -34.56M |
| Shares Out | 47.43M |
| EPS (ttm) | -0.73 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 16 |
| Last Price | $4.92 |
| Previous Close | $4.86 |
| Change ($) | 0.06 |
| Change (%) | 1.23% |
| Day's Open | 4.87 |
| Day's Range | 4.67 - 4.98 |
| Day's Volume | 2,543,986 |
| 52-Week Range | 1.63 - 6.59 |
NEW YORK, April 08, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today ann...
PAVmed to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference
On-demand corporate presentation scheduled for March 17, 2021
NEW YORK, March 03, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announc...
NEW YORK, March 01, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today ann...
NEW YORK, Feb. 25, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announce...
NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announce...
NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announce...
Announces majority-owned subsidiary Lucid Diagnostics intends to spin-off into a separate public company
Conference call and live webcast was previously scheduled for 4:30 PM EST
NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today anno...
NEW YORK, Feb. 09, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announce...
NEW YORK, Jan. 08, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announce...
NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announce...
NEW YORK, Dec. 22, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announce...
NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announce...
NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announce...
PAVmed's (PAVM) CEO Lishan Aklog on Q3 2020 Results - Earnings Call Transcript
Conference call to be held today at 4:30 p.m. Eastern time
NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announce...
The company has multiple promising medical devices in various states of regulatory approval, although three of these have already entered the commercial stage. Yet, like for most pre-revenue medical dev...
NEW YORK, Sept. 08, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today annou...
PAVmed Inc. (PAVM) CEO Lishan Aklog on Q2 2020 Results and Business Update - Earnings Call Transcript
Conference call to be held today at 4:30 p.m. Eastern time
NEW YORK, Aug. 06, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announ...
NEW YORK, July 28, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announ...
NEW YORK, July 13, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announ...
NEW YORK, June 17, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced the Company is ...
NEW YORK, June 15, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that medical di...
NEW YORK, June 11, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that its majori...
Executed LOI with Canon Virginia, Inc. to develop and implement commercial grade processes to manufacture molded resorbable pediatric ear tubes from aqueous silk fibroin
PAVMed Is About To Enter The Commercialization Phase
PAVmed Inc. (PAVM) CEO Lishan Aklog on Q1 2020 Results and Business Update - Earnings Call Transcript
Conference call to be held today at 4:30 p.m. Eastern time
PAVmed: Small Medical Device Maker With New FDA Approval And Multiple Catalysts
NEW YORK, April 21, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced it has receive...
PAVmed Inc. (PAVM) CEO Lishan Aklog on Q4 2019 Results - Earnings Call Transcript
Conference call to be held today at 4:30 p.m. Eastern time
NEW YORK, April 02, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the EsoCh...
NEW YORK, March 31, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced it has receive...
Incorporates data from successful clinical safety study in which all patients met pre-specified safety and effectiveness endpoints
Study to assess EsoCheck as a less invasive, more efficient, and cost-effective alternative to endoscopic biopsies for rapidly emerging allergy-mediated condition which currently requires multiple and f...
Lucid secures exclusive option to license biomarker technology to detect progression from nondysplastic to dysplastic BE using EsoCheck to allow curative ablation before deadly esophageal cancer develops
Disposable single-use device designed to provide safer, more efficient and cost-effective ablation of dysplastic Barrett’s Esophagus, complementing Lucid Diagnostics’ EsoGuard™ and EsoCheck™ products
NEW YORK, Feb. 11, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the Compan...
NEW YORK, Jan. 13, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced it has received...
First commercially available DNA test designed to facilitate the diagnosis of Barrett’s Esophagus and related precursors to highly lethal form of esophageal cancer
NEW YORK, Dec. 13, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today provided an update on its...
PAVmed Has Multiple Paths To Growth
PAVmed Inc. (PAVM) CEO Lishan Aklog on Q3 2019 Results - Earnings Call Transcript
Conference call to be held on November 21, 2019 at 4:30 p.m. Eastern time
About PAVM
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE). Its product pipeline also comprises EsoGuard, a molecular diagnostic esophageal DNA test; EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusi... [Read more...]
| Industry Medical Devices | IPO Date Apr 28, 2016 |
| Stock Exchange NASDAQ | Ticker Symbol PAVM |
Analyst Forecasts
According to 3 analysts, the average rating for PAVmed stock is "Strong Buy." The 12-month stock price forecast is 8.50, which is an increase of 72.76% from the latest price.